Clinical News-CliniExpert

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate

PLYMOUTH MEETING, Pa., Aug. 26, 2021 -- INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and

ALXN1840 FoCus Phase III Trial in Wilson Disease Met Primary Endpoint Demonstrating Improvement in Copper Mobilisation from Tissues

ALXN1840 demonstrated approximately three times greater copper mobilisation from tissues than standard-of-care treatments 26 August 2021 -- Positive high-level results from the FoCus Phase III trial i

CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival

VANCOUVER, Washington, Aug. 25, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 a

Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems

GAITHERSBURG, Md., Aug. 25, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Novavax

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

NEW YORK, Aug. 24, 2021 -- Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled and ran

Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis

DUBLIN and SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmace

AZD7442 PROVENT Phase III Prophylaxis Trial Met Primary Endpoint in Preventing COVID-19

77% reduced risk of developing symptomatic COVID-19 First long-acting antibody combination to prevent COVID-19 20 August 2021 -- Positive high-level results from the PROVENT Phase III pre-exposure pro

NRx Pharmaceuticals Announces Positive Safety Report for Zyesami (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19

After Review of Approximately 140 patients in ACTIV-3 Critical Care Study, No New Safety Concerns Raised by Independent Data Safety Monitoring Board, Study to Continue Enrollment to Target More than 6

Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone Data support the use of toripalimab with chemotherapy as first-line therapy for pa

Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer

SOUTH SAN FRANCISCO, August 18, 2021 -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engin

Statement on Boosting with the Johnson & Johnson COVID-19 Vaccine

NEW BRUNSWICK, N.J., August 18, 2021 -- We are engaging with the U.S. FDA, CDC and other health authorities and will share new data shortly regarding boosting with the Johnson & Johnson COVID-19 v

Lilly's Lebrikizumab Significantly Improved Skin Clearance and Itch in People with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials

INDIANAPOLIS, Aug. 16, 2021 /PRNewswire/ -- Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (